Comparison between suba Itraconazole (SB) and conventional Itraconazole in the treatment of dermatophytosis.

Comparison of efficacy and safety between suba Itraconazole (SB) and conventional Itraconazole in the treatment of dermatophytosis: A Randomised observer blinded pilot study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/11/038062

Enrollment

Registered

2021-11-15

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Suba Itraconazole 50mg: All patients meeting the eligibility criteria will be randomised into two equal groups. Group A will recieve cap Suba Itraconazole (50mg) via oral route, to be

Eligibility

Inclusion criteria

Inclusion criteria: All patients of dermatophytosis beyond 18 year of age.

Exclusion criteria

Exclusion criteria: 1. Patients with prior use of systemic and/or topical antifungals in last 1 month. 2. Pregnancy and lactation 3. Deranged hepatic and renal status. 4. Diabetes mellitus. 5. History of cardiac disease.

Design outcomes

Primary

Measure	Time frame
Compare the efficacy of itraconazole 100 mg twice daily dosing with SB itraconazole 50 mg twice daily at the end of two weeks in dermatophytosis.Timepoint: At end of 2 weeks.	—

Secondary

Measure	Time frame
Compare the safety of itraconazole 100 mg twice daily dosing with SB itraconazole 50 mg twice daily at the end of two weeks in dermatophytosis.Timepoint: At the end of 2 weeks.	—

Countries

India

Contacts

Public ContactDr Bikash Ranjan Kar

IMS and SUM Hospital

karbikash@gmail.com9937428181

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026